Population-based trends in high-grade cervical lesions in the early human papillomavirus vaccine era in the United States-Reference-Cited by-同舟云学术

Population-based trends in high-grade cervical lesions in the early human papillomavirus vaccine era in the United States

Published:2015-06-22 Issue:16 Volume:121 Page:2775-2781
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Hariri Susan¹,Johnson Michelle L.¹,Bennett Nancy M.²,Bauer Heidi M.³,Park Ina U.³,Schafer Sean⁴,Niccolai Linda M.⁵,Unger Elizabeth R.⁶,Markowitz Lauri E.¹,

Affiliation:

1. Division of STD Prevention; National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention; Atlanta Georgia

2. Center for Community Health and Department of Medicine; University of Rochester School of Medicine and Dentistry; Rochester New York

3. STD Control Branch; HIV/STD/TB Program; Center for Public Health Practice, California Department of Public Health; Richmond California

4. HIV/STD/TB Program; Center for Public Health Practice, Oregon Public Health Division; Portland Oregon

5. Department of Epidemiology of Microbial Diseases; Yale School of Public Health; New Haven Connecticut

6. Division of High-Consequence Pathogens and Pathology; National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention; Atlanta Georgia

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference13 articles.

1. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia;Bosch;Vaccine,2008

2. Chapter 2: natural history of anogenital human papillomavirus infection and neoplasia;Schiffman;J Natl Cancer Inst Monogr,2003

3. FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP);Centers for Disease Control and Prevention;MMWR Morb Mortal Wkly Rep,2010

4. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial;Dillner;BMJ,2010

5. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial;Lehtinen;Lancet Oncol,2012

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The 2023 Korean sexually transmitted infections guidelines by the Korean Association of Urogenital Tract Infection and Inflammation: Human papillomavirus vaccination;Investigative and Clinical Urology;2024

2. Impact of human papillomavirus vaccine on cervical cancer epidemic: Evidence from the surveillance, epidemiology, and end results program;Frontiers in Public Health;2023-01-06

3. Human Papillomavirus Infection and the Risk of Erectile Dysfunction: A Nationwide Population-Based Matched Cohort Study;Journal of Personalized Medicine;2022-04-27

4. Population Trends and Long-term Outlook for Oropharyngeal Cancer;JAMA Otolaryngology–Head & Neck Surgery;2022-02-01

5. Real-world impact and effectiveness assessment of the quadrivalent HPV vaccine: a systematic review of study designs and data sources;Expert Review of Vaccines;2021-12-13